Clinical Trial Update: Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and immune response of a recombinant live-attenuated parainfluenza virus type 1 vaccine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parainfluenza Virus Infection

Drugs mentioned

• Recombinant live-attenuated parainfluenza virus type 1 vaccine (parainfluenza virus type 1 vaccine, recombinant, live-attenuated)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Parainfluenza, Virus Diseases | Phase 1 | Status: COMPLETED